1. Valle, JW . Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345–vii348.
Google Scholar | Crossref | Medline2. Bridgewater, J, Lopes, A, Palmer, D, et al. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer. 2016;114(9):965-971.
Google Scholar | Crossref3. Valle, J, Wasan, H, Palmer, DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-1281.
Google Scholar | Crossref4. Snyder, A, Makarov, V, Merghoub, T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-2199.
Google Scholar | Crossref | Medline | ISI5. Rizvi, NA, Hellmann, MD, Snyder, A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128.
Google Scholar | Crossref | Medline | ISI6. Tella, SH, Kommalapati, A, Borad, MJ, et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21(1):e29-e41.
Google Scholar | Crossref | Medline7. Marabelle, A, Fakih, M, Lopez, J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353-1365.
Google Scholar | Crossref8. Kim, RD, Chung, V, Alese, OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888-894.
Google Scholar | Crossref9. Valle, JW, Lamarca, A, Goyal, L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943-962.
Google Scholar | Crossref10. Nakamura, H, Arai, Y, Totoki, Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003-1010.
Google Scholar | Crossref11. Boilève, A, Hilmi, M, Smolenschi, C, et al. Immunotherapy in advanced biliary tract cancers. Cancers (Basel). 2021;13(7):1569.
Google Scholar12. Boilève, A, Hilmi, M, Delaye, M, et al. Biomarkers in hepatobiliary cancers: what is useful in clinical practice? Cancers (Basel. 2021;13(11):2708.
Google Scholar13. Samstein, RM, Lee, CH, Shoushtari, AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202-206.
Google Scholar | Crossref14. Goodman, AM, Kato, S, Bazhenova, L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598-2608.
Google Scholar | Crossref15. Osipov, A, Lim, SJ, Popovic, A, et al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis. Clin Cancer Res. 2020;26(18):4842-4851.
Google Scholar | Crossref16. Gbolahan, O, Hashemi-Sadraei, N, O’Neil, B. Prolonged response to anti-PD-1 antibody therapy in chemotherapy-refractory cholangiocarcinoma with high tumor mutational burden. J Natl Compr Canc Netw. 2019;17(6):644-648.
Google Scholar | Crossref17. Rizzo, A, Ricci, AD, Brandi, G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel. 2021;13(3):558.
Google Scholar18. Vogel, A, Bathon, M, Saborowski, A. Immunotherapies in clinical development for biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):351-363.
Google Scholar | Crossref | Medline19. Rizzo, A, Ricci, AD, Brandi, G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):527-536.
Google Scholar | Crossref20. Holland, AJ, Cleveland, DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol. 2009;10(7):478-487.
Google Scholar | Crossref21. McShane, LM, Altman, DG, Sauerbrei, W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.
Google Scholar | Crossref | Medline | ISI22. Nikanjam, M, Riviere, P, Goodman, A, et al. Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology. 2020;9(1):1781997.
Google Scholar | Crossref23. Riviere, P, Goodman, AM, Okamura, R, et al. High tumor mutational burden correlates with longer survival in immunotherapy-naïve patients with diverse cancers. Mol Cancer Ther. 2020;19(10):2139-2145.
Google Scholar | Crossref24. Zhang, W, Shi, J, Wang, Y, et al. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. Cancer Immunol Immunother. 2021;70(4):1001-1014.
Google Scholar | Crossref